Sitemap
- About Us
- Gene Editing
- Animal & Cell Models
- Efficacy & Toxicity Studies
- In Vivo Efficacy
- PK/PD & In vitro Pharmacology Studies
- Efficacy & Toxicity Case Studies
- Inflammatory Disease Modeling
- EAE Model
- Asthma Model
- Psoriasis Model
- Atopic Dermatitis Model
- Rheumatoid Arthritis Model
- Inflammatory Bowel Disease Model
- Acute Lung Injury & Inflammation Models
- Bleomycin-Induced Pulmonary Fibrosis Model
- Delayed type hypersensitivity model
- LPS-Induced Acute Inflammation Model
- OVX-Induced Osteoporosis Model
- Systemic Lupus Erythematosus Model
- Metabolic Disease Modeling
- Type 2 diabetes model
- HFMCD induced NASH Model
- Western Diet induced NASH Model
- Carbon Tetrachloride (CCl4)-induced Model
- Bile duct ligation-induced liver fibrosis Mouse Model
- Acetaminophen-induced Liver Injury Model
- Concanavalin A hepatitis model
- TAA (Thioacetamide) -induced liver fibrosis Mouse Model
- Antibody Discovery
- RenMab™
- Pipeline
- Agonistic anti-CD40 IgG2 antibody YH003
- Anti-CTLA-4 IgG1 monoclonal antibody YH001
- Anti-OX40 IgG1 antibody YH002
- Agonistic anti-4-1BB IgG1 antibody YH004
- Anti-Claudin 18.2 antibody ADC YH005
- Anti-PD-1 x CD40 bispecific antibody YH008
- HER2 x TROP2 bispecific ADC YH012
- EGFR x MET bispecific ADC YH013
- Antagonistic anti-CD40 fully human antibody YH015
- Antibody Hits In Discovery
- Careers
- News & Resources
- Investors
